Characterization of the Structural Features and Interactions of Sclerostin

The secreted glycoprotein sclerostin has recently emerged as a key negative regulator of Wnt signaling in bone and has stimulated considerable interest as a potential target for therapeutics designed to treat conditions associated with low bone mass, such as osteoporosis. We have determined the structure of sclerostin, which resulted in the identification of a previously unknown binding site for heparin, suggestive of a functional role in localizing sclerostin to the surface of target cells. We have also mapped the interaction site for an antibody that blocks the inhibition of Wnt signaling by sclerostin. This shows minimal overlap with the heparin binding site and highlights a key role for this region of sclerostin in protein interactions associated with the inhibition of Wnt signaling. The conserved N- and C-terminal arms of sclerostin were found to be unstructured, highly flexible, and unaffected by heparin binding, which suggests a role in stabilizing interactions with target proteins.

[1]  P. Kostenuik,et al.  Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  M. Forster,et al.  Application of drug discovery software to the identification of heparin-binding sites on protein surfaces: a computational survey of the 4-helix cytokines , 2008 .

[3]  M. Carr,et al.  Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR , 2008, Oncogene.

[4]  M. Yavropoulou,et al.  The role of the Wnt signaling pathway in osteoblast commitment and differentiation. , 2007, Hormones.

[5]  P. T. Choong,et al.  Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A , 2007, Oncogene.

[6]  Mark L. Johnson,et al.  The Wnt signaling pathway and bone metabolism , 2007, Current opinion in rheumatology.

[7]  Xi He,et al.  LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST* , 2006, Journal of Biological Chemistry.

[8]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[9]  Scott Saunders,et al.  Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  H. Vrieling,et al.  Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP‐Stimulated Bone Formation , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  V. Nurcombe,et al.  Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. , 2006, Gene.

[12]  Sabrina Cattaruzza,et al.  Approaching the proteoglycome: molecular interactions of proteoglycans and their functional output. , 2006, Macromolecular bioscience.

[13]  M. Forster,et al.  Computational approaches to the identification of heparin-binding sites on the surfaces of proteins. , 2006, Biochemical Society transactions.

[14]  K. Garcia,et al.  Structure of artemin complexed with its receptor GFRalpha3: convergent recognition of glial cell line-derived neurotrophic factors. , 2006, Structure.

[15]  C. Robinson,et al.  Structural basis for the inhibition of activin signalling by follistatin , 2006, The EMBO journal.

[16]  M. Carr,et al.  NMR Assignment and Secondary Structure Determination of the C-terminal MA-3 Domain of the Tumour Suppressor Protein Pdcd4 , 2006, Journal of Biomolecular NMR.

[17]  M. Carr,et al.  NMR Assignment of the mTOR Domain Responsible for Rapamycin Binding , 2006, Journal of biomolecular NMR.

[18]  J. Reeve,et al.  The FASEB Journal express article 10.1096/fj.05-4221fje. Published online August 25, 2005. ©2005 FASEB , 2022 .

[19]  Xi He,et al.  SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor* , 2005, Journal of Biological Chemistry.

[20]  Peng Liu,et al.  Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.

[21]  H. Schreuder,et al.  Crystal structure of recombinant human growth and differentiation factor 5: evidence for interaction of the type I and type II receptor-binding sites. , 2005, Biochemical and biophysical research communications.

[22]  Wayne A. Hendrickson,et al.  Structure of human follicle-stimulating hormone in complex with its receptor , 2005, Nature.

[23]  Xinhua Lin,et al.  Functions of heparan sulfate proteoglycans in cell signaling during development , 2004, Development.

[24]  J. Latham,et al.  Noggin and Sclerostin Bone Morphogenetic Protein Antagonists Form a Mutually Inhibitory Complex* , 2004, Journal of Biological Chemistry.

[25]  M. Karperien,et al.  Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist , 2004, The Journal of experimental medicine.

[26]  Geoffrey J. Barton,et al.  The Jalview Java alignment editor , 2004, Bioinform..

[27]  John A Latham,et al.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.

[28]  Nobuyuki Itoh,et al.  Sclerostin Is a Novel Secreted Osteoclast-derived Bone Morphogenetic Protein Antagonist with Unique Ligand Specificity* , 2003, Journal of Biological Chemistry.

[29]  Ajamete Kaykas,et al.  Zebrafish Prickle, a Modulator of Noncanonical Wnt/Fz Signaling, Regulates Gastrulation Movements , 2003, Current Biology.

[30]  P. Beighton,et al.  The natural history of sclerosteosis , 2003, Clinical genetics.

[31]  Jens Bollerslev,et al.  Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. , 2003, American journal of human genetics.

[32]  C. Dominguez,et al.  HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.

[33]  Markus Affolter,et al.  Structural basis of BMP signalling inhibition by the cystine knot protein Noggin , 2002, Nature.

[34]  Torsten Herrmann,et al.  Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. , 2002, Journal of molecular biology.

[35]  R. Kelley,et al.  IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding , 2001, The EMBO journal.

[36]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[37]  D. Galas,et al.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.

[38]  R. Fletterick,et al.  Crystal structure of neurotrophin-3 homodimer shows distinct regions are used to bind its receptors. , 1998, Biochemistry.

[39]  R. Williamson,et al.  High Resolution Structure of the N-terminal Domain of Tissue Inhibitor of Metalloproteinases-2 and Characterization of Its Interaction Site with Matrix Metalloproteinase-3* , 1998, The Journal of Biological Chemistry.

[40]  R. Williamson,et al.  Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation. , 1997, Biochemistry.

[41]  A. D. de Vos,et al.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Charles Eigenbrot,et al.  X-ray structure of glial cell-derived neurotrophic factor at 1.9 Å resolution and implications for receptor binding , 1997, Nature Structural Biology.

[43]  R. Wait,et al.  Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography , 1997, Thrombosis and Haemostasis.

[44]  R. Huber,et al.  Crystal structure of a coagulogen, the clotting protein from horseshoe crab: a structural homologue of nerve growth factor. , 1996, The EMBO journal.

[45]  K. Constantine,et al.  Localizing the NADP+ binding site on the MurB enzyme by NMR , 1996, Nature Structural Biology.

[46]  J. Schrader,et al.  A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. M. F. Aalten,et al.  PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules , 1996, J. Comput. Aided Mol. Des..

[48]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[49]  D. Stuart,et al.  Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. , 1995, Biochemistry.

[50]  W A Hendrickson,et al.  Structure of human chorionic gonadotropin at 2.6 A resolution from MAD analysis of the selenomethionyl protein. , 1994, Structure.

[51]  C. Sander,et al.  Protein structure comparison by alignment of distance matrices. , 1993, Journal of molecular biology.

[52]  M. Forster,et al.  N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.

[53]  W. Hendrickson,et al.  A structural superfamily of growth factors containing a cystine knot motif , 1993, Cell.

[54]  F. Winkler,et al.  Crystal structure of human platelet‐derived growth factor BB. , 1992, The EMBO journal.

[55]  M. Grütter,et al.  An unusual feature revealed by the crystal structure at 2.2 Å resolution of human transforming growth fact or-β2 , 1992, Nature.

[56]  K Wüthrich,et al.  Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints , 1991, Journal of biomolecular NMR.

[57]  O. Avsian-Kretchmer,et al.  Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. , 2004, Molecular endocrinology.

[58]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[59]  G J Kleywegt,et al.  Model building and refinement practice. , 1997, Methods in enzymology.